BR112018012164A2 - anticorpos neutralizantes do vírus da imunodeficiência humana - Google Patents
anticorpos neutralizantes do vírus da imunodeficiência humanaInfo
- Publication number
- BR112018012164A2 BR112018012164A2 BR112018012164A BR112018012164A BR112018012164A2 BR 112018012164 A2 BR112018012164 A2 BR 112018012164A2 BR 112018012164 A BR112018012164 A BR 112018012164A BR 112018012164 A BR112018012164 A BR 112018012164A BR 112018012164 A2 BR112018012164 A2 BR 112018012164A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunodeficiency virus
- human immunodeficiency
- neutralizing antibodies
- virus neutralizing
- methods
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 title 1
- 230000036436 anti-hiv Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção fornece anticorpos anti-hiv com propriedades terapêuticas melhoradas, composições farmacêuticas relacionadas e métodos de uso dos mesmos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562267652P | 2015-12-15 | 2015-12-15 | |
PCT/US2016/066658 WO2017106346A2 (en) | 2015-12-15 | 2016-12-14 | Human immunodeficiency virus neutralizing antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018012164A2 true BR112018012164A2 (pt) | 2018-12-04 |
Family
ID=58737847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018012164A BR112018012164A2 (pt) | 2015-12-15 | 2016-12-14 | anticorpos neutralizantes do vírus da imunodeficiência humana |
Country Status (37)
Country | Link |
---|---|
US (3) | US10239935B2 (pt) |
EP (2) | EP3992206A1 (pt) |
JP (4) | JP6732915B2 (pt) |
KR (1) | KR102165120B1 (pt) |
CN (2) | CN109311967B (pt) |
AR (1) | AR106991A1 (pt) |
AU (3) | AU2016370591C1 (pt) |
BR (1) | BR112018012164A2 (pt) |
CA (1) | CA3008442C (pt) |
CL (1) | CL2018001587A1 (pt) |
CO (1) | CO2018006050A2 (pt) |
CR (1) | CR20180321A (pt) |
CU (1) | CU20180062A7 (pt) |
CY (1) | CY1124756T1 (pt) |
DK (1) | DK3390441T3 (pt) |
DO (2) | DOP2018000146A (pt) |
EA (2) | EA201891186A1 (pt) |
EC (1) | ECSP18045028A (pt) |
ES (1) | ES2897756T3 (pt) |
HU (1) | HUE056243T2 (pt) |
IL (1) | IL259832B (pt) |
LT (1) | LT3390441T (pt) |
MA (1) | MA44077A (pt) |
MX (2) | MX2018007288A (pt) |
MY (2) | MY196200A (pt) |
NZ (1) | NZ743713A (pt) |
PE (1) | PE20181451A1 (pt) |
PH (1) | PH12018501281A1 (pt) |
PL (1) | PL3390441T3 (pt) |
SA (1) | SA518391778B1 (pt) |
SG (2) | SG10202108793TA (pt) |
SI (1) | SI3390441T1 (pt) |
SV (1) | SV2018005710A (pt) |
TW (2) | TWI735491B (pt) |
UA (1) | UA125819C2 (pt) |
WO (1) | WO2017106346A2 (pt) |
ZA (1) | ZA201803783B (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
HRP20211456T1 (hr) | 2014-12-26 | 2021-12-24 | Emory University | Protuvirusni derivati n4-hidroksicitidina |
ES2894304T3 (es) | 2015-10-25 | 2022-02-14 | Sanofi Sa | Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH |
PE20181451A1 (es) | 2015-12-15 | 2018-09-12 | Gilead Sciences Inc | Anticuerpos neutralizadores del virus de inmunodeficiencia humana |
TWI788286B (zh) | 2016-04-13 | 2023-01-01 | 法商賽諾菲公司 | 三特異性和/或三價結合蛋白 |
FI3443006T3 (fi) | 2016-04-13 | 2023-10-23 | Sanofi Sa | Trispesifisiä ja/tai kolmiarvoisia sitojaproteiineja |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
KR102324568B1 (ko) | 2017-06-21 | 2021-11-10 | 길리애드 사이언시즈, 인코포레이티드 | HIV gp120 및 CD3을 표적화하는 다중특이적 항체 |
JP6804790B1 (ja) | 2017-12-07 | 2020-12-23 | エモリー ユニバーシティー | N4−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 |
WO2019125846A1 (en) * | 2017-12-19 | 2019-06-27 | The Rockefeller University | HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION |
CN111971299A (zh) * | 2018-02-21 | 2020-11-20 | 美国政府(由卫生和人类服务部的部长所代表) | HIV-1 Env的中和抗体及其用途 |
EP3797118A4 (en) * | 2018-05-22 | 2022-06-29 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
CA3100282A1 (en) * | 2018-06-19 | 2019-12-26 | Nantcell, Inc. | Hiv treatment compositions and methods |
CA3102859A1 (en) | 2018-07-03 | 2020-01-09 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
EP3849607A4 (en) * | 2018-09-13 | 2022-06-22 | Children's National Medical Center | CELLS COMPRISING ANTIBODIES TARGETING HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF PREPARING THEM AND USE THEREOF |
WO2020086782A1 (en) * | 2018-10-24 | 2020-04-30 | The Wistar Institute Of Anatomy And Biology | Dna antibody constructs for use against hiv |
BR112021012094A2 (pt) * | 2018-12-19 | 2021-08-31 | Humabs Biomed Sa | Anticorpos isolados, proteína de fusão, polinucleotídeos isolados, vetor, célula hospedeira, composição farmacêutica, kit, método de produção, usos, métodos de tratamento, prevenção e/ou atenuação, de diagnóstico in vitro e para detectar a presença ou ausência de um epítopo |
BR112021013415A2 (pt) * | 2019-01-07 | 2021-12-28 | Univ Jefferson | Proteínas de fusão multifuncionais e usos das mesmas |
LT3938047T (lt) | 2019-03-22 | 2022-10-10 | Gilead Sciences, Inc. | Tilteliniai tricikliniai karbamoilpiridono junginiai ir jų naudojimas farmacijoje |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
TW202231277A (zh) * | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
TW202116800A (zh) * | 2019-07-08 | 2021-05-01 | 美國洛克菲勒大學 | 多反應性降低之抗hiv疫苗抗體 |
KR20220047277A (ko) | 2019-07-16 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
JP7502861B2 (ja) | 2019-12-27 | 2024-06-19 | 旭化成株式会社 | 標的物質と両親媒性高分子との複合体の形成反応の反応温度の評価方法 |
WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
WO2021207635A1 (en) * | 2020-04-09 | 2021-10-14 | The George Washington University | Prussian blue nanoparticles functionalization with latency reversing agents and broadly neutralizing antibodies, and applications thereof |
BR112023003366A2 (pt) | 2020-08-25 | 2023-05-09 | Gilead Sciences Inc | Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de uso |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
CN116437958A (zh) | 2020-11-11 | 2023-07-14 | 吉利德科学公司 | 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法 |
WO2022272275A1 (en) * | 2021-06-25 | 2022-12-29 | Janssen Vaccines & Prevention B.V. | Combinations of vaccines and neutralizing antibodies for treating human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
CN118355020A (zh) | 2021-12-03 | 2024-07-16 | 吉利德科学公司 | Hiv病毒感染的治疗性化合物 |
IL312718A (en) | 2021-12-03 | 2024-07-01 | Gilead Sciences Inc | Therapeutic compounds for HIV infection |
US20230212148A1 (en) | 2021-12-03 | 2023-07-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
US20240034724A1 (en) | 2022-07-01 | 2024-02-01 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5913521B2 (ja) | 1975-06-19 | 1984-03-30 | メイトウサンギヨウ カブシキガイシヤ | 磁性酸化鉄・デキストラン複合体の製造法 |
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4454106A (en) | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
PT81498B (pt) | 1984-11-23 | 1987-12-30 | Schering Ag | Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US7041293B1 (en) | 1990-04-03 | 2006-05-09 | Genentech, Inc. | HIV env antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
EA014685B1 (ru) | 2003-04-25 | 2010-12-30 | Джилид Сайэнс, Инк. | Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе |
KR20120083534A (ko) | 2004-02-06 | 2012-07-25 | 메다렉스, 인코포레이티드 | 클로스트리듐 디피실리 독소에 대한 항체 및 이의 용도 |
ATE505196T1 (de) | 2004-07-27 | 2011-04-15 | Gilead Sciences Inc | Nukleosid phosphonat konjugate als anti hiv mittel |
AU2005302416A1 (en) | 2004-10-29 | 2006-05-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies |
EP1817340B1 (en) | 2004-11-12 | 2012-05-16 | Xencor, Inc. | Fc variants with altered binding to fcrn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
CA2611998A1 (en) | 2005-06-13 | 2006-12-21 | Cargill, Incorporated | Objective methods of estimating age of animals and carcasses |
TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯 |
AU2006299429B2 (en) | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
EP1803814A1 (en) | 2005-12-27 | 2007-07-04 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Method of improving the antibody selection capacity in phage-display library |
US20080279879A1 (en) | 2006-11-17 | 2008-11-13 | New York University | INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE |
JP4783325B2 (ja) | 2007-04-09 | 2011-09-28 | 株式会社神戸製鋼所 | 高温排ガスの処理方法 |
US7968544B2 (en) | 2007-06-29 | 2011-06-28 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
EA201200631A1 (ru) | 2007-11-16 | 2012-11-30 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
DK2313111T3 (da) | 2008-08-01 | 2013-12-02 | Ventirx Pharmaceuticals Inc | Toll-lignende receptoragonistformuleringer og anvendelse deraf |
US8840890B2 (en) | 2008-11-12 | 2014-09-23 | University Of Maryland, Baltimore | Rapid expression cloning of human monoclonal antibodies from memory B cells |
CN102272134B (zh) | 2008-12-09 | 2013-10-16 | 吉里德科学公司 | Toll样受体调节剂 |
CA2753082A1 (en) | 2009-02-20 | 2010-08-26 | International Aids Vaccine Initiative | Recombinant viral vectors |
SI3260136T1 (sl) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa |
EP2246364A1 (en) | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
US8691809B2 (en) | 2009-08-18 | 2014-04-08 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
RU2580320C2 (ru) | 2009-08-18 | 2016-04-10 | Вентиркс Фармасьютикалз, Инк. | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора |
SI2491035T1 (sl) | 2009-10-22 | 2017-10-30 | Gilead Sciences, Inc. | Derivati purina ali deazapurina uporabni za zdravljenje (med drugimi) virusnih okužb |
WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
CA2802492C (en) | 2010-07-02 | 2018-10-16 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
CN103140474A (zh) | 2010-07-02 | 2013-06-05 | 吉里德科学公司 | 治疗aids的萘-2-基乙酸衍生物 |
CN102374226A (zh) | 2010-08-06 | 2012-03-14 | 深圳富泰宏精密工业有限公司 | 套筒、铰链结构及应用该铰链结构的便携式电子装置 |
EP2611465A4 (en) | 2010-08-31 | 2014-06-04 | Theraclone Sciences Inc | NEUTRALIZING ANTI-VIRUS ANTIBODIES FOR HUMAN IMMUNODEFICIENCY (HIV) |
MX2013003632A (es) | 2010-09-28 | 2013-05-20 | Fujitsu Ltd | Metodo y estacion de base, equipo de usuario y sistema para activar el modo de trabajo de coexistencia. |
ES2616449T3 (es) | 2010-10-01 | 2017-06-13 | Ventirx Pharmaceuticals, Inc. | Uso terapéutico de un agonista de TLR y terapia de combinación |
WO2012045089A2 (en) | 2010-10-01 | 2012-04-05 | Ventirx Pharmaceuticals, Inc. | Methods for the treatment of allergic diseases |
KR101416437B1 (ko) | 2010-11-03 | 2014-07-10 | 한국전자통신연구원 | 파장 가변 외부 공진 레이저 발생 장치 |
CN107011333B (zh) | 2010-11-18 | 2021-03-19 | 耶鲁大学 | 具有募集抗体并对人体免疫缺陷病毒进入有抑制活性的双功能分子 |
ES2620606T3 (es) | 2011-01-12 | 2017-06-29 | Ventirx Pharmaceuticals, Inc. | Benzoazepinas sustituidas como moduladores de receptores tipo Toll |
CA2824786A1 (en) | 2011-01-12 | 2012-07-19 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
WO2012106578A1 (en) * | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
ES2691745T3 (es) | 2011-04-08 | 2018-11-28 | Janssen Sciences Ireland Uc | Derivados de pirimidina para el tratamiento de infecciones víricas |
EP3181555B1 (en) | 2011-04-21 | 2018-11-28 | Gilead Sciences, Inc. | Benzothiazole compounds and their pharmaceutical use |
PT2709989T (pt) | 2011-05-18 | 2018-03-27 | Janssen Sciences Ireland Uc | Derivados de quinazolina para o tratamento de infeções virais e outras doenças |
ES2553449T3 (es) | 2011-07-06 | 2015-12-09 | Gilead Sciences, Inc. | Compuestos para el tratamiento de VIH |
CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
EP2794613B1 (en) | 2011-12-20 | 2017-03-29 | Boehringer Ingelheim International GmbH | Condensed triclyclic compounds as inhibitors of hiv replication |
WO2013096744A1 (en) | 2011-12-21 | 2013-06-27 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
DK2812331T3 (en) | 2012-02-08 | 2019-04-08 | Janssen Sciences Ireland Unlimited Co | PIPERIDINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS |
ES2668422T3 (es) | 2012-04-20 | 2018-05-18 | Gilead Sciences, Inc. | Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH |
US11149069B2 (en) | 2012-08-03 | 2021-10-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers |
AU2013301450B2 (en) | 2012-08-10 | 2018-01-18 | Janssen Sciences Ireland Uc | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases |
SG11201502622VA (en) | 2012-10-10 | 2015-05-28 | Janssen Sciences Ireland Uc | PYRROLO[3,2-<i>D</i>]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES |
EP2925729B1 (en) | 2012-11-16 | 2017-10-18 | Janssen Sciences Ireland UC | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
PT3608325T (pt) | 2012-12-21 | 2022-10-17 | Gilead Sciences Inc | Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica |
US10087178B2 (en) | 2012-12-27 | 2018-10-02 | Japan Tobacco Inc. | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor |
WO2014124457A1 (en) * | 2013-02-11 | 2014-08-14 | University Of Louisville Research Foundation, Inc. | Methods for producing antibodies |
US9598378B2 (en) | 2013-02-21 | 2017-03-21 | Janssen Sciences Ireland Uc | 2-aminopyrimidine derivatives for the treatment of viral infections |
WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
CA2932405A1 (en) | 2013-12-02 | 2015-06-11 | Aaron Diamond Aids Research Center | Improved hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture |
MX2017000026A (es) * | 2014-07-11 | 2017-05-01 | Gilead Sciences Inc | Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih). |
CU20180011A7 (es) | 2015-03-04 | 2018-06-05 | Gilead Sciences Inc | Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll |
PE20181451A1 (es) | 2015-12-15 | 2018-09-12 | Gilead Sciences Inc | Anticuerpos neutralizadores del virus de inmunodeficiencia humana |
-
2016
- 2016-12-14 PE PE2018001115A patent/PE20181451A1/es unknown
- 2016-12-14 EA EA201891186A patent/EA201891186A1/ru unknown
- 2016-12-14 NZ NZ743713A patent/NZ743713A/en unknown
- 2016-12-14 TW TW105141486A patent/TWI735491B/zh active
- 2016-12-14 PL PL16867376T patent/PL3390441T3/pl unknown
- 2016-12-14 SG SG10202108793TA patent/SG10202108793TA/en unknown
- 2016-12-14 CA CA3008442A patent/CA3008442C/en active Active
- 2016-12-14 EP EP21192543.3A patent/EP3992206A1/en active Pending
- 2016-12-14 BR BR112018012164A patent/BR112018012164A2/pt active Search and Examination
- 2016-12-14 AR ARP160103833A patent/AR106991A1/es unknown
- 2016-12-14 MX MX2018007288A patent/MX2018007288A/es unknown
- 2016-12-14 SI SI201631372T patent/SI3390441T1/sl unknown
- 2016-12-14 SG SG11201804787UA patent/SG11201804787UA/en unknown
- 2016-12-14 DK DK16867376.2T patent/DK3390441T3/da active
- 2016-12-14 CU CUP2018000062A patent/CU20180062A7/es unknown
- 2016-12-14 EP EP16867376.2A patent/EP3390441B1/en active Active
- 2016-12-14 US US15/379,157 patent/US10239935B2/en active Active
- 2016-12-14 UA UAA201806361A patent/UA125819C2/uk unknown
- 2016-12-14 EA EA202091898A patent/EA202091898A1/ru unknown
- 2016-12-14 AU AU2016370591A patent/AU2016370591C1/en active Active
- 2016-12-14 MY MYPI2021003644A patent/MY196200A/en unknown
- 2016-12-14 CR CR20180321A patent/CR20180321A/es unknown
- 2016-12-14 TW TW110130315A patent/TWI814056B/zh active
- 2016-12-14 JP JP2018530831A patent/JP6732915B2/ja active Active
- 2016-12-14 HU HUE16867376A patent/HUE056243T2/hu unknown
- 2016-12-14 MA MA044077A patent/MA44077A/fr unknown
- 2016-12-14 KR KR1020187019806A patent/KR102165120B1/ko active IP Right Grant
- 2016-12-14 MY MYPI2018702243A patent/MY186414A/en unknown
- 2016-12-14 CN CN201680079823.5A patent/CN109311967B/zh active Active
- 2016-12-14 ES ES16867376T patent/ES2897756T3/es active Active
- 2016-12-14 WO PCT/US2016/066658 patent/WO2017106346A2/en active Application Filing
- 2016-12-14 LT LTEPPCT/US2016/066658T patent/LT3390441T/lt unknown
- 2016-12-14 CN CN202210281565.6A patent/CN114848812A/zh active Pending
-
2018
- 2018-06-05 IL IL259832A patent/IL259832B/en unknown
- 2018-06-07 ZA ZA2018/03783A patent/ZA201803783B/en unknown
- 2018-06-11 SA SA518391778A patent/SA518391778B1/ar unknown
- 2018-06-13 DO DO2018000146A patent/DOP2018000146A/es unknown
- 2018-06-13 SV SV2018005710A patent/SV2018005710A/es unknown
- 2018-06-13 CL CL2018001587A patent/CL2018001587A1/es unknown
- 2018-06-13 EC ECIEPI201845028A patent/ECSP18045028A/es unknown
- 2018-06-13 CO CONC2018/0006050A patent/CO2018006050A2/es unknown
- 2018-06-14 PH PH12018501281A patent/PH12018501281A1/en unknown
- 2018-06-14 MX MX2022013524A patent/MX2022013524A/es unknown
-
2019
- 2019-02-12 US US16/273,753 patent/US10882898B2/en active Active
- 2019-12-05 AU AU2019275625A patent/AU2019275625B2/en active Active
-
2020
- 2020-05-14 JP JP2020085079A patent/JP6936361B2/ja active Active
- 2020-12-03 US US17/110,876 patent/US11655285B2/en active Active
-
2021
- 2021-01-29 DO DO2021000022A patent/DOP2021000022A/es unknown
- 2021-08-26 JP JP2021137876A patent/JP7126594B2/ja active Active
- 2021-11-04 AU AU2021261910A patent/AU2021261910B2/en active Active
- 2021-11-10 CY CY20211100980T patent/CY1124756T1/el unknown
-
2022
- 2022-08-16 JP JP2022129584A patent/JP2022163192A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018012164A2 (pt) | anticorpos neutralizantes do vírus da imunodeficiência humana | |
CL2017001610A1 (es) | Anticuerpos humanos para hemagglutinina de influenza | |
CL2017003261A1 (es) | Factor xi anticuerpos y métodos de uso | |
BR112017012344A2 (pt) | anticorpos anti-c10orf54 e usos dos mesmos | |
MA43108A (fr) | Anticorps neutralisant le virus syncytial respiratoire humain | |
EP3525821A4 (en) | MULTI-SPECIFIC ANTIBODIES TARGETING THE HUMAN IMMUNODEFICIENCY VIRUS AND THEIR METHODS OF USE | |
BR112018075651A2 (pt) | anticorpos anti-cd98 e conjugados anticorpo fármaco | |
BR112016019176A2 (pt) | anticorpos il-21 | |
BR112018002382A8 (pt) | Novos anticorpos anti-gvpi humano e usos dos mesmos | |
CL2017000212A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
EA201890457A1 (ru) | Комбинации антитела против ox40 и модулятора tlr4 и их применение | |
UY36261A (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
BR112019023742A2 (pt) | anticorpos anti-trkb | |
BR112016029935A2 (pt) | ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo? | |
EA201700254A1 (ru) | Комбинация | |
BR112017005993A2 (pt) | derivados de peptídeo inovadores e usos dos mesmos | |
EA202091403A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
JOP20180058A1 (ar) | أجسام مضادة محيدة لفيروس نقص المناعة البشرية |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |